IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer.


Journal

Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624

Informations de publication

Date de publication:
17 04 2020
Historique:
received: 12 09 2018
revised: 02 11 2019
accepted: 26 03 2020
entrez: 19 4 2020
pubmed: 19 4 2020
medline: 1 1 2021
Statut: ppublish

Résumé

Dendritic cells play a key role in the orchestration of antitumor immune responses. The cDC1 (conventional dendritic cell 1) subset has been shown to be essential for antitumor responses and response to immunotherapy, but its precise role in humans is largely unexplored. Using a multidisciplinary approach, we demonstrate that human cDC1 play an important role in the antitumor immune response through their capacity to produce type III interferon (IFN-λ). By analyzing a large cohort of breast primary tumors and public transcriptomic datasets, we observed specific production of IFN-λ1 by cDC1. In addition, both IFN-λ1 and its receptor were associated with favorable patient outcomes. We show that IFN-III promotes a T

Identifiants

pubmed: 32303573
pii: 5/46/eaav3942
doi: 10.1126/sciimmunol.aav3942
pii:
doi:

Substances chimiques

Interferons 9008-11-1
Interferon Lambda 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Margaux Hubert (M)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France.
Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), Lyon, France.

Elisa Gobbini (E)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France.
CHU Grenoble-Alpes, France.

Coline Couillault (C)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France.

Thien-Phong Vu Manh (TV)

Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.

Anne-Claire Doffin (AC)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France.

Justine Berthet (J)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France.
Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), Lyon, France.

Céline Rodriguez (C)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France.
Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), Lyon, France.

Vincent Ollion (V)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France.
LabEx DEVweCAN, Lyon, France.

Janice Kielbassa (J)

Synergie Lyon Cancer, Plateforme de Bio-informatique 'Gilles Thomas', Lyon, France.

Christophe Sajous (C)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France.

Isabelle Treilleux (I)

Centre Léon Bérard, F-69008 Lyon, France.

Olivier Tredan (O)

Centre Léon Bérard, F-69008 Lyon, France.

Bertrand Dubois (B)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France.
Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), Lyon, France.

Marc Dalod (M)

Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.

Nathalie Bendriss-Vermare (N)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France.
Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), Lyon, France.
LabEx DEVweCAN, Lyon, France.

Christophe Caux (C)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France.
Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), Lyon, France.
LabEx DEVweCAN, Lyon, France.
Centre Léon Bérard, F-69008 Lyon, France.

Jenny Valladeau-Guilemond (J)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, 69008, France. jenny.valladeau@lyon.unicancer.fr.
LabEx DEVweCAN, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH